Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study of Saquinavir/Ritonavir in Liver-Impaired Patients With HIV Infection.
- First Posted Date
- 2007-02-16
- Last Posted Date
- 2018-03-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 16
- Registration Number
- NCT00435929
VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant Recipients
Phase 4
Completed
- Conditions
- Cytomegalovirus Infections
- Interventions
- First Posted Date
- 2007-02-05
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 325
- Registration Number
- NCT00431353
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
- First Posted Date
- 2007-02-01
- Last Posted Date
- 2017-08-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 545
- Registration Number
- NCT00430352
- Locations
- 🇦🇺
Mount Medical Center, Perth, Western Australia, Australia
🇧🇷Clinica Oncologica De Piracicaba Sc, Piracicaba, SP, Brazil
🇩🇪Dres.Andreas Karcher und Stefan Fuxius, Heidelberg, Germany
A Study of CellCept (Mycophenolate Mofetil) in Patients With Lupus Nephritis.
Phase 3
Terminated
- Conditions
- Lupus Nephritis
- Interventions
- First Posted Date
- 2007-01-23
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 52
- Registration Number
- NCT00425438
A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a TNF-Blocker.
Phase 4
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2007-01-19
- Last Posted Date
- 2016-05-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 20
- Registration Number
- NCT00424502
A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
- First Posted Date
- 2007-01-18
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 306
- Registration Number
- NCT00423501
A Pharmacokinetic and Pharmacodynamic Study of MabThera (Rituximab) Plus Methotrexate in Patients With Rheumatoid Arthritis (RA)
Phase 2
Terminated
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2007-01-17
- Last Posted Date
- 2014-07-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 3
- Registration Number
- NCT00422942
A Study Comparing Mircera and Epoetin Alfa for the Treatment of Anemia in Dialysis Patients With Chronic Kidney Disease.
Phase 3
Terminated
- Conditions
- Anemia
- Interventions
- First Posted Date
- 2007-01-17
- Last Posted Date
- 2011-12-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 260
- Registration Number
- NCT00422513
A Study of Retreatment With MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (RA)
- First Posted Date
- 2007-01-17
- Last Posted Date
- 2015-05-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 378
- Registration Number
- NCT00422383
A Study of CellCept (Mycophenolate Mofetil) in Kidney Transplant Patients Switched From EC-MPS.
Phase 4
Terminated
- Conditions
- Kidney Transplantation
- First Posted Date
- 2007-01-11
- Last Posted Date
- 2007-11-20
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT00420472
© Copyright 2025. All Rights Reserved by MedPath